Friday, June 20, 2014

Clinical Trial Of Soliris Starting For Myasthenia Gravis Patients

The FDA (Food and Drug Administration) has allowed orphan drug status for Alexion Pharmaceuticals' Soliris (eculizumab) for treating patients with Myasthenia Gravis (MG). Myasthenia Gravis a rare, debilitating neuromuscular disorder brought on by uncontrolled complement activation. In patients with MG, such complement activation due to antibodies directed at the neuromuscular junction can ultimately lead to profound and debilitating weakness of various muscle groups throughout the body.

Alexion announced it is currently enrolling patients

Monday, June 16, 2014

Headaches In MG Patients Should Be Treated - Researchers Say

Many myasthenia gravis patients often complain that they have headaches. But, there hasn't been much in the way of  studies on the relation between chronic headaches and myasthenia gravis (MG). So, doctors at the Department of Neurology, School of Medicine, at Keio University in Japan conducted a clinical study aimed to discover if MG symptoms affect the development or worsening of chronic headache.

In the study of the participating 184 myasthenia